DOSAGE INDEX / BLEND
KLOW
Research, reported schedules and supply planning.
Understand what KPV intestinal research contributes to the KLOW rationale and why a four-ingredient listing does not establish added repair benefit.
Source: PeptideDosages.com. Independently written summaries of reported protocols, not validated treatment recommendations. Reviewed for transcription on September 21, 2026.
Research Protocol & Dosage
Source-reported examples · not treatment recommendations
- Amount
- 2–6 mg total per day across the source examples
- Frequency
- Once daily
- Cycle / observation period
- 8–12 weeks; source also mentions 16 weeks
- Route / research model
- Subcutaneous
The source assumes 50 mg GHK-Cu and 10 mg each of BPC-157, TB-500 and KPV per vial. Component evidence does not validate the combined schedule.
Titration & progression
The phases below describe the named source example, not an instruction to increase a dose. Product-label schedules and research examples are identified separately.
| Phase | Amount per administration | Frequency |
|---|---|---|
| Days 1–14 | 2 mg | Daily |
| Days 15–28 | 4 mg | Daily |
| Days 29–56 | 6 mg | Daily |
| Days 57–84 | 4 mg | Daily |
Supply & Planning
Compare vial strengths here. A different vial size changes the available material, not the biological dose.
Diluent & formulation
Diluent compatibility is formulation-specific. A verified manufacturer instruction is still needed before bacteriostatic water or another diluent can be listed as suitable for this research material.
Vial comparison
Source example: 84-day planning window: 364 mg total material. Use this total below, or enter a different documented total for comparison.
| Vial strength | Vials needed |
|---|---|
| 80 mg | 5 |
Calculated from the displayed schedule.
Material minimum only: round total material ÷ vial content up to a whole vial. Actual supply may be higher because of single-use packaging, discard dates, dead space or losses. No validated multi-use storage period is assumed.
Reported Research Results
Selected observations from the cited research. Each finding retains its study population, formulation and limitations.
Studies of individual ingredients do not establish the effects of this finished combination. Combination studies are identified explicitly below.
- The reference catalog describes KLOW as GHK-Cu, BPC-157, TB-500 and KPV. That is the composition of the listing, not proof that the four-component mixture is clinically effective or that every similarly named product is identical.
- Original KPV research examined uptake through PepT1 in intestinal and immune-cell systems and reported reduced inflammatory signaling. The work also included experimental mouse colitis. It did not test KLOW. [1]
- A separate KPV study reported favorable inflammatory and recovery measures in two mouse colitis models. These were experimental intestinal-disease outcomes, not a trial of a four-peptide repair mixture. [2]
Sourcing & Vendor Information
No compound-specific affiliate destination is listed here yet. Browse the Vendors Index for the available supplier records and disclosed relationships.
Sources & Further Reading
Medical publications and supporting literature from the corresponding protocol bibliographies, combined across vial strengths. Supplier and commercial catalog references are excluded. Duplicate destinations appear once. Inclusion does not mean that a paper validates the reported dose, or that an ingredient study tests the finished blend.
Bibliography checked September 22, 2026: 14 entries mapped from 1 source page. Medical and supporting references are retained below; supplier entries are excluded.
- Original study
- Original mouse report
- PubMedFurther reading · Listed in reference bibliography.
- PubMedFurther reading · Listed in reference bibliography.
- PMCFurther reading · Listed in reference bibliography.
- PMCFurther reading · Listed in reference bibliography.
- PMCFurther reading · Listed in reference bibliography.
- PMCFurther reading · Listed in reference bibliography.
- PMCFurther reading · Listed in reference bibliography.
- PMCFurther reading · Listed in reference bibliography.
- CDCGeneral guidance · Listed in reference bibliography.
- CDCGeneral guidance · Listed in reference bibliography.
- NCBI BookshelfFurther reading · Listed in reference bibliography.
- PubMedFurther reading · Listed in reference bibliography.
- PMCFurther reading · Listed in reference bibliography.
Reported schedule reference: PeptideDosages.com. Research findings are summarized independently from the listed sources.